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a–g Saudi ArabiaBackground: Diabetes mellitus (DM) is a major public health problem in Saudi Arabia. DM patients who present
with acute coronary syndrome (ACS) have worse cardiovascular outcomes. We characterized clinical features and
hospital outcomes of diabetic patients with ACS in Saudi Arabia.
Methods: ACS patients enrolled in the Saudi Project for Assessment of Acute Coronary Syndrome (SPACE) study
from December 2005 to December 2007, either with DM or newly diagnosed during hospitalization were eligible.
Baseline demographics, clinical presentation, therapies, and in-hospital outcomes were compared with non-diabetic
patients.
Results: Of the 5055 ACS patients enrolled in SPACE, 2929 (58.1%) had DM (mean age 60.2 ± 11.5, 71.6% male, and
87.6% Saudi nationals). Diabetic patients had higher risk-factor (e.g., hypertension, hyperlipidemia) prevalences and
were more likely to present with non–ST-elevation myocardial infarction (40.2% vs. 31.4%, p < 0.001), heart failure
(25.4% vs. 13.9%, p < 0.001), significant left ventricular systolic dysfunction and multi-vessel disease. Diabetic
patients had higher in-hospital heart failure, cardiogenic shock, and re-infarction rates. Adjusted odds ratio for
in-hospital mortality in diabetic patients was 1.83 (95% CI, 1.02–3.30, p = 0.042).
Conclusions: A substantial proportion of Saudi patients presenting with ACS have DM and a significantly worse
prognosis. These data highlight the importance of cardiovascular preventative interventions in the general
population.
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Diabetes is a major public health problemworldwide and a growing cause of vascular
disease, including coronary artery disease [1].
The prevalence of diabetes in Saudi Arabia is esti-
mated to be 23.7% and is considered one of the
highest in the world [2]. Diabetic patients present-
ing with acute coronary syndrome (ACS) have a
worse prognosis [3], and diabetes prevalence in
ACS populations is higher in Middle Eastern
countries when compared to other regions[4]
however, no data exist regarding diabetes in Saudi
patients presenting with ACS. Our objective was
to document the risk profile, mode of presenta-
tion, therapeutic interventions, and hospital out-
comes of diabetic patients presenting with ACS
using data from the Saudi Project for Acute Coro-
nary Events (SPACE) registry.Methods
The SPACE registry is a prospective, multicen-
ter, observational study of all consecutive ACS pa-
tients admitted to the participating hospitals. The
study was conducted from the start of December
2005 until the end of December 2007. The full
description of the methods has been published
previously [5]. Seventeen urban hospitals in five
regions of Saudi Arabia were involved in the
SPACE registry.
Data collection was performed using a standard-
ized Case Report Form and included the following
variables: demographics, past medical history,
provisional diagnosis on admission and final dis-
charge diagnosis, ECG findings, laboratory inves-
tigations, medical therapy used on admission
during hospitalization and on discharge, use of
cardiac procedures and interventions, adverse
in-hospital outcomes, and in-hospital mortality.
Diabetes status was based on self reporting or
the finding of a fasting blood sugar more than
6.9 mmol/dl [5] on hospital admission. Baseline
characteristics, hospital therapies, and clinical ad-
verse outcomes were compared with data for non-
diabetic patients. Ethics approval was obtained
from the institutional review boards in all partici-
pating hospitals.Statistical analysis
Categorical data were summarized as absolute
numbers and percentages. Continuous data were
summarized as means and standard deviations
(SDs) or medians with inter-quartile ranges
(IQRs). Comparison between groups for categori-cal data was done using chi-square or Fisher’s ex-
act tests, while the student’s T tests or Wilcoxon
rank sum tests were used for continuous vari-
ables. Multiple logistic regression models were
used to estimate the adjusted odds ratio (OR),
adjusting for gender, age, nationality, smoking,
prior history of coronary artery disease (CAD),
prior history of peripheral artery disease, history
of dyslipidemia, body mass index, serum creati-
nine, heart rate, systolic blood pressure, percuta-
neous coronary intervention (PCI), coronary
artery bypass grafting (CABG), coronary angio-
gram, and all in-hospital medications. All tests
were two-sided, with a 5% level of significance.
All analyses were performed using SAS/STAT
software.Results
A total of 5055 patients were enrolled in the
SPACE registry; of these, 2929 (57.9%) were dia-
betic patients (92.8% known diabetic patients
and 7.2% newly diagnosed during their index hos-
pitalization). Of the diabetic population, 902
(30.8%) were on insulin, 1871 (63.9%) on oral hypo-
glycemic agents, and 156 (5.3%) were using
diet alone.
Table 1 shows the baseline characteristics and
key risk factors for DM and non-DM patients with
ACS. Diabetic patients were more likely to be old-
er, female, and Saudi nationals. In addition, dia-
betic patients were significantly more likely to
have hypertension, dyslipidemia, and a past his-
tory of vascular disease, and to have undergone
revascularization procedures, both PCI and
CABG. On the other hand, diabetic patients were
significantly less likely to be smokers.
Upon hospital presentation, diabetic patients
were more likely to be diagnosed with non-
ST-elevation myocardial infarction (NSTEMI) or
unstable angina compared to non-diabetic pa-
tients (40.2% vs. 31.4%, and 22.6% vs. 21.1%,
respectively), and less likely to present with ST-
elevation myocardial infarction (STEMI). (37.2%
vs 47.5%); p 6 0.001 for all comparisons.
DM patients were more likely to present with
heart failure (25.4% vs. 20.6%, p < 0.001) and tachy-
cardia (17.9% vs. 10.5%, p < 0.001). Moreover, dia-
betic patients were significantly more likely to
harbor a higher-risk coronary anatomy, defined
as severe three-vessel disease or significant left
main stem coronary disease, and to have signifi-
cant left ventricular systolic dysfunction (Table 1).
With regard to hospital pharmacological thera-
pies, no significant differences were detected
Table 1. Baseline characteristics and clinical presentation.
Variables Total Non-DM DM p-Value
Age (mean, ±SD) 58.0 (12.92) 55.0 (14.13) 60.0 (11.46) <0.001
Female (%) 1138 (22.55) 305 (14.43) 833 (28.40) <0.001
Saudi (%) 4154 (82.42) 1586 (75.20) 2568 (87.62) <0.001
HTN (%) 2776 (55.25) 829 (39.63) 1947 (66.41) <0.001
Dyslipidemia (%) 2082 (41.47) 620 (29.67) 1462 (49.88) <0.001
Smoking (%) 1634 (32.41) 949 (44.93) 685 (23.39) <0.001
Prior CAD (%) 2138 (42.45) 737 (34.93) 1401 (47.88) <0.001
Prior PCI (%) 698 (14) 238 (11.5) 460 (15.8) <0.001
Prior CABG (%) 296 (5.87) 97 (4.60) 199 (6.79) <0.001
Prior PAD (%) 364 (7.24) 71 (3.38) 293 (10.02) <0.001
Prior CVA (%) 308 (6.12) 69 (3.28) 239 (8.16) <0.001
BMI, median (IQR) 27.6 (5.34) 27.3 (5.27) 27.8 (5.37) <0.001
Waist circumference, median (IQR) 98.0 (18.10) 97.0 (18.12) 100.0 (17.90) <0.001
Hemoglobin (g/dl), mean (±SD) 13.8 (3.09) 14.2 (1.93) 13.5 (3.28) <0.001
Serum creatinine (lmol), mean (±SD) 107 (78.98) 102.45 (73.3) 110.58 (82.8) <0.001
Fasting blood sugar (mmol/dl), mean (±SD) 7.7 (3.59) 5.9 (1.89) 8.9 (3.43) <0.001
LDL cholesterol (mmol/dl), mean (±SD) 2.9 (2.73) 3.0 (2.29) 2.7 (1.59) <0.001
HR > 100 (%) 677 (14.86) 203 (10.57) 474 (17.98) <0.001
SBP < 90 mmHg (%) 147 (3.23) 51 (2.65) 96 (3.65) 0.061
Heart failure (%) 935 (20.57) 267 (13.95) 668 (25.39) <0.001
LVEF (<35%) (%) 1710 (36.32) 602 (30.68) 1108 (40.35) <0.001
3VD/LM (%) 1220 (35.90) 386 (27.41) 834 (41.91) <0.001
Abbreviations: HTN, hypertension; CAD, coronary artery disease; PCI, percutaneous coronary intervention; CABG, coronary artery bypass grafting;
PAD, peripheral arterial disease; CVA, cerebrovascular accident; BMI, body mass index; LDL, low-density lipoprotein; HR, heart rate; SBP, systolic
blood pressure; LVEF, left ventricular ejection fraction; 3VD/LM, three-vessel and left main diseases.
Table 2. Hospital therapies.
Variables Total Non-DM DM p-Value
Aspirin (%) 4921 (97.76) 2066 (97.96) 2855 (97.61) 0.402
Clopidogrel (%) 4218 (83.81) 1755 (83.25) 2463 (84.21) 0.366
B-blockers (%) 4112 (81.72) 1724 (81.74) 2388 (81.70) 0.965
ACEI (%) 3500 (69.57) 1391 (65.96) 2109 (72.18) <0.001
ARB (%) 296 (5.91) 96 (4.57) 200 (6.87) <0.001
Statins (%) 4698 (93.33) 1965 (93.17) 2733 (93.44) 0.711
Heparin (%) 4166 (82.64) 1735 (82.15) 2431 (83) 0.433
GP IIb IIIa inhibitors (%) 1385 (27.47) 588 (27.84) 797 (27.21) 0.621
Thrombolyticsa (%) 1149 (60.70) 598 (65.00) 551 (56.63) <0.001
Symptoms onset to hospital arrival time, minutes, median (IQR) 153 (210) 135 (204) 173 (205) 0.002
DNT, median (IQR) 53.0 (60.0) 50.0 (53.0) 60.0 (74.0) 0.001
DNT < 30 mina (%) 142 (19.78) 90 (22.61) 52 (16.25) 0.033
Primary PCIa (%) 158 (17.32) 81 (16.49) 77 (18.33) 0.46
DBT, median (IQR) 109.0 (68.5) 101.5 (47.0) 123.5 (85.0) 0.060
PCI (%) 1775 (35.32) 825 (39.14) 950 (32.56) <0.001
CABG (%) 425 (8.49) 140 (6.66) 285 (9.80) <0.001
Length of hospital stay, median (±SD) 5.0 (32.33) 4.0 (32.92) 5.0 (31.98) 0.491
Abbreviations: ACEI, angiotensin converting enzyme inhibitors; ARB, angiotensinogen receptor blockers; DNT, door-to-needle time; PCI, percuta-
neous coronary intervention; DBT, door-to-balloon time; CABG, coronary artery bypass grafting.
a Proportions were out of STEMI patients receiving reperfusion therapy.
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IMPACT OF DIABETES ON HOSPITALbetween DM and non-DM patients with a few
exceptions (Table 2). The use of angiotensin con-
verting enzyme inhibitors (ACE-I) and angioten-
sin receptor blockers (ARBs) was greater in the
diabetes population. Conversely, diabetic patients
with STEMI were less likely to receive thrombo-
lytic therapy (56.6% vs. 65%, p < 0.001), and if they
did receive it, had a longer door to needle time(DNT), with a smaller percentage achieving the
standard DNT of less than 30 min. Primary PCI
was less used in diabetic patients, and there was
a strong trend for a longer door to balloon time.
With respect to revascularization procedures,
diabetic patients were less likely to undergo elec-
tive PCI but were more likely to undergo CABG.
Fig. 1 depicts the rates of hospital adverse
Figure 1. Diabetes proportion in the SPACE registry compared to
other ACS registries.
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ischemic attacks and major bleeding, diabetic
patients had significantly higher rates of all
adverse cardiovascular outcomes.
On univariate analysis, diabetic patients with
ACS were more likely to develop heart failure,
recurrent myocardial infarction, and cardiogenic
shock and to die in-hospital (Table 3).
On multivariate analysis, DM, though with a
mildly attenuated influence, remained an inde-
pendent predictor for all-cause hospital mortality
(OR 1.8, 95% confidence interval (CI) 1.02–3.30)
and heart failure (OR 1.84, 95% CI 1.33–2.54); how-
ever, it was not a predictor for other adverse hos-
pital outcomes (Table 3).Discussion
SPACE is the first national ACS registry in Saudi
Arabia. We have found that almost two thirds of
ACS patients enrolled in this registry were dia-
betic. To our knowledge, this is the highest DM
prevalence ever reported in an ACS population
and is two to three times higher than that reported
in other ACS registries [6–15] (Fig. 1). Moreover,
the prevalence of DM in the SPACE registryTable 3. Odds ratios (ORs) for developing in hospital events in dia
Outcomes Crude OR(95% CI) p-V
Death 2.02 (1.40–2.91) <0.
Heart failure 2.95 (2.35–3.70) <0.
Re-MI 1.75 (1.05–2.94) 0.0
Cardiogenic shock 1.73 (1.28–2.34) 0.0
Stroke 1.44 (0.77–2.70) 0.2
Major bleeding 1.36 (0.80–2.30) 0.2
Abbreviations: Re-MI, recurrent myocardial infarction.
a Covariates adjustment for include: gender, age, nationality, smoking, pri
artery disease, history of dyslipidemia, body mass index, serum creatinine,
(PCI), coronary artery bypass grafting (CABG), coronary angiogram, and allseems higher than that reported in neighboring
Gulf countries. The Gulf Registry of Acute Coro-
nary Events (Gulf RACE) has identified a preva-
lence of approximately 40% [16]. Although this
prevalence is considered high compared to wes-
tern registries, it is significantly lower than that
found in the SPACE registry. A higher proportion
of expatriates in the Gulf RACE, who are usually
healthier and younger, could potentially explain
this observation [16].
Given that newly diagnosed diabetic patients
were a small minority, including them under the
known diabetic patients group did not change
the adjusted associations between Diabetic pa-
tients status and adverse outcomes.
In the late 1970s and early 1980s, diabetes was
not considered a commonly encountered medical
diagnosis in Saudi Arabia, as Saudi males had a
similar prevalence of diabetes compared to other
parts of the world [17]. This situation, however,
seems to have changed dramatically in the last
two decades, as the prevalence of diabetes in Sau-
di Arabia is now one of the highest in the world
[18]. The high DM prevalence in our registry is ex-
pected and probably reflects the high DM preva-
lence in the general population. Several
mechanisms have been proposed to explain this
phenomenon in the Saudi population, including
a sedentary lifestyle, adopting the ‘‘western diet,’’
and the fast pace of urbanization [17,19]. Some
have proposed that the indigenous Saudi popula-
tion has a special genetic predisposition to devel-
oping type 2 diabetes; this groundwork is further
amplified by a high rate of consanguinity, a rise
in obesity rates, and the presence of other compo-
nents of insulin resistance syndrome [20,21].
We have shown that diabetic patients with ACS
have several unique features compared with their
non-diabetic counterparts. Diabetic patients have
a higher prevalence of traditional risk factors for
CAD such as hypertension, hyperlipidemia, and
abdominal obesity. Additionally, diabetic patients
were more likely to have had vascular disease orbetic patients with acute coronary syndrome (ACS).
alue Adjusted ORa (95% CI) p-Value
0001 1.83 (1.02–3.30) 0.042
0001 1.84 (1.33–2.54) <0.0001
316 1.15 (0.53–2.50) 0.7133
003 1.50 (0.97–2.33) 0.0657
468 1.16 (0.53–2.55) 0.7039
438 1.69 (0.76–3.71) 0.1911
or history of coronary artery disease (CAD), prior history of peripheral
heart rate, systolic blood pressure, percutaneous coronary intervention
in-hospital medications.
Figure 2. Rates of hospital adverse outcomes in diabetic vs. non-
diabetic patients.
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IMPACT OF DIABETES ON HOSPITALprevious coronary revascularization procedures.
These findings are in accordance with the findings
of the Global Registry of Acute Coronary Events
(GRACE) as well as the Greek study of ACS
(GREECS) [10,22].
Diabetic patients in this study had features of
high risk at presentation. Heart failure on presen-
tation to the emergency room was almost double
in diabetic patients compared to non-diabetic pa-
tients. Moreover, patients with diabetes were
found to have worse left ventricular systolic dys-
function and a higher-risk coronary anatomy.
These findings in conjunction with higher rates
of NSTEMI may reflect the diffuse nature of coro-
nary atherosclerosis in diabetic patients and a
higher burden of ischemia[23], and is similar to
what was reported in other registries such as the
Indian ACS registry (CREATE) [15].
The median time from symptom onset to presen-
tation to the emergency room in diabetic patients
was 173 min, and was longer compared to non-dia-
betic patients. This is significantly longer than the
overall delay seen in other ACS registries, such as
the 145 min reported in the second European
Heart Survey ([24], 140 min reported in the
GRACE Registry [10], or the 128 min reported in
the US National Registry of Myocardial Infarction
[25]. Possible explanations for this delay include
atypical symptoms and a higher prevalence of si-
lent ischemia in diabetic patients [15].
With regard to diabetic patients presenting with
STEMI, we found that thrombolytic agents were
given less frequently, and once given had a pro-
longed DNT compared to non-DM patients. A
plausible explanation for this delay is again atyp-
ical presentation, which might have delayed the
establishment of a STEMI diagnosis. Primary
PCI was done only in 18.3% of diabetic patients
with STEMI, a rate much lower than that reported
in registry data from western countries [10]. There
was a strong statistical trend towards a longer
median door-to-balloon time, which might have
been significant if the sample size had been larger.
Pharmacological therapies were generally simi-
lar in diabetic versus non-diabetic patients except
for a higher use of ACE inhibitors and ARBs, a
finding seen also in the GRACE registry [23].
The rates of in-hospital mortality, recurrent
myocardial infarction, cardiogenic shock, and
heart failure were significantly higher among dia-
betic patients, and diabetic status was an indepen-
dent predictor for mortality, heart failure, and
cardiogenic shock after adjusting for potential
confounders. The rate of in-hospital mortality
was less than what has been reported from theGREECS (5.6%) and CREATE (6.7%) registries;
the main reasons for the lower in-hospital mortal-
ity in our study could potentially be the younger
age of diabetic patients relative to other western
registries and possibly improved overall socioeco-
nomic status and higher use of guideline-based
therapies compared to the CREATE registry.
Our findings present numerous challenges. Pri-
mary prevention measures to counteract the epi-
demic of a high prevalence of diabetes in the
general population, such as educational campaigns
focusing on healthy diets, weight control, and exer-
cise, will be of paramount importance in reducing
future acute vascular events. In addition, diabetes
management through multidisciplinary clinics or
diabetic centers is needed to reduce long-term
complications. Educating diabetic patients about
symptoms of ACS can potentially reduce some of
the delays seen in administering reperfusion ther-
apies in our registry and potentially decrease ad-
verse cardiac events. On the other hand, the high
prevalence of diabetes in ACS patients presents
ample opportunities for research focusing on
understanding why diabetes portends a worse
prognosis in ACS patients at a molecular level, as
well as exploring novel therapeutic interventions
through randomized controlled trials.
This study has several limitations. There is an
inherent selection bias because of the observa-
tional nature of the study design and the possibility
of missing unmeasured important co-variables. In
addition, factors leading to delays in the adminis-
tration of reperfusion therapies were not prospec-
tively collected. Moreover, the SPACE registry
did not address long-term outcomes and may have
led to a potential underestimation of the overall
prognosis for diabetic patients with ACS.
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2012;24:225–231In conclusion, this first Saudi national ACS reg-
istry revealed one of the highest diabetes preva-
lences ever reported in an ACS cohort. It also
identified several important management gaps
compared to non-diabetic patients and confirmed
the relatively poor adverse cardiac outcomes seen
in other contemporary registries (see Fig. 2).Financial disclosure
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